It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Yes, the ACAM2000 is a live replicating vaccinia virus vaccine that, per the adverse reactions listed on the warnings insert, can cause severe disability, inflammation of the brain and spinal cord, permanent neurological sequelae (long term infection), death of the vaccinated individual, and … wait for it… “death of unvaccinated individuals who have contact with vaccinated individuals.” You cannot make this stuff up.
The CDC website on mpox vaccination states that ACAM2000 “has not been used in the ongoing clade II mpox outbreak that started in 2022″ but “has been made available for use against mpox in the clade II outbreak under an Expanded Access Investigational New Drug (EA-IND) protocol, which requires informed consent along with completing additional forms.”
The guide — which the FDA requires to be given to patients before they get the ACAM2000 vaccine — says, “ACAM2000 can cause serious complications in vaccinated individuals and in their close contacts to whom the vaccine virus has spread.”
Karl Jablonowski, Ph.D. — senior research scientist at Children’s Health Defense — told The Defender that the FDA’s approval of the shot is a “public hazard, not the practice of public health.”
“You can call ACAM2000 a ‘vaccine,’ but its impact on the United States will be as a ‘disease,’” Jablonowski said.
He added:
“For instance, the drug’s package insert reveals (see Table 3) that the U.S. Department of Health and Human Services (HHS) found roughly 520 per million ACAM2000 recipients contracted myocarditis or pericarditis.
“That is about 1 in 2,000. But elsewhere in the package insert, the FDA acknowledges that — based on additional studies — the risk is actually 5.7 per 1,000 vaccinations.
“That’s about 1 in every 175 people. If the 262 million adults in the U.S. received this vaccine, an estimated 1,493,000 would contract the serious adverse reaction of myopericarditis.”
Dr. Meryl Nass, an internist and biological warfare expert, told The Defender that the CDC also acknowledged this same figure — myopericarditis in 5.7 per 1,000 primary ACAM2000 vaccinations — during a June 23, 2022, meeting.
“It’s a huge number,” Nass said. “The fact that the FDA and CDC are acknowledging it means no one should get the vaccine.”
She explained:
“Myopericarditis is a life-threatening condition. It lowers your life expectancy.
“For instance, the drug’s package insert reveals (see Table 3) that the U.S. Department of Health and Human Services (HHS) found roughly 520 per million ACAM2000 recipients contracted myocarditis or pericarditis.
“That is about 1 in 2,000. But elsewhere in the package insert, the FDA acknowledges that — based on additional studies — the risk is actually 5.7 per 1,000 vaccinations.
“That’s about 1 in every 175 people. If the 262 million adults in the U.S. received this vaccine, an estimated 1,493,000 would contract the serious adverse reaction of myopericarditis.”
“Myopericarditis is a life-threatening condition. It lowers your life expectancy.
“Most people are never going to be exposed to mpox or smallpox. Vaccines are typically given to healthy people who are never even going to be exposed, therefore the risk posed by the vaccine needs to be low.
“That’s why vaccine safety is critical — even more than drugs, because drugs are given to people who are already sick.
“This risk — 1 in 175 — is higher than all other licensed vaccines for which the CDC acknowledges side effects. This is the worst.”